Diffuse large B-cell lymphoma (DLBCL) presenting with hyperlactatemia or lactic acidosis (LA) represents a rare, often fatal paraneoplastic ...

Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It develops when abnormal B cells rapidly accumulate in lymph nodes, causing painless swelling often in the ...

Beqalzi (sonrotoclax) is the first BCL2 inhibitor indicated for MCL patients who have progressed after at least 2 lines of therapy, including a BTK inhibitor.

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...

T-cell therapy continues to reshape the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (R ...

Florida State University chemists have synthesized new molecules derived from bacteria found in a Pacific Ocean sea sponge, a ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, ...